Pragma announces relaunch of Moxatag

NEW YORK — Pragma Pharmaceuticals announced the relaunch of Moxatag (amoxicillin extended-release tablets), 775 mg. The company acquired Moxatag from Shionogi Inc. in March 2014 and has been working to make the product available in time for the 2014-15 cold-and-flu season.



“Amoxicillin is the gold standard in treating strep pharyngitis. Simplifying the dosing regimen is a no brainer. Greater convenience to help patient compliance is key to ensuring effective antibiotic therapy,” a Pragma spokesperson said.



Moxatag is indicated for the treatment of tonsillitis and/or pharyngitis secondary to streptococcus pyogenes (S. pyogenes) in adult and pediatric patients 12 years of age or older, the company said. Fera Pharmaceuticals will manage the sales and marketing of Moxatag for Pragma.